BARD1 Life Sciences Ltd
ASX:BD1
BARD1 Life Sciences Ltd
Inventory
BARD1 Life Sciences Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BARD1 Life Sciences Ltd
ASX:BD1
|
Inventory
AU$47.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Inventory
AU$275.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Inventory
AU$2.5m
|
CAGR 3-Years
26%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Inventory
AU$15.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Inventory
AU$15.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Inventory
AU$35m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
BARD1 Life Sciences Ltd
Glance View
BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.
See Also
What is BARD1 Life Sciences Ltd's Inventory?
Inventory
47.5k
AUD
Based on the financial report for Jun 30, 2021, BARD1 Life Sciences Ltd's Inventory amounts to 47.5k AUD.
